Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
| Autor: | Ivan Adamec, Dunja Rogić, Monika-Gabriele Penz, Carola Braun, Mario Habek |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Adult
Male Multiple Sclerosis Short Communication Immunology Immunity Humoral / immunology Antibodies Monoclonal Humanized Antibodies Viral Multiple Sclerosis / immunology Antibodies T-cell immunity Antibodies Viral / blood Immunology and Allergy Humans COVID-19 / complications Immunity Cellular COVID-19 Ofatumumab COVID-19 / immunology Immunity Humoral Immunity Cellular / immunology Neurology Clinical Trials Phase III as Topic Multiple Sclerosis / complications Antibodies Monoclonal Humanized / therapeutic use Female Neurology (clinical) |
| Zdroj: | Journal of Neuroimmunology |
| Popis: | Objectives To report clinical outcome, development of humoral and T-cell mediated immunity in convalescent COVID-19 people with multiple sclerosis (pwMS) treated with ofatumumab in the ALITHIOS study from a single center. Methods Testing for SARS-Cov2 IgG antibodies was performed on two occasions with at least three months apart between the two testing. During the second antibody testing, interferon-γ ELISpot was used to assess cellular immunity. Results All four subjects had mild COVID-19 infection without any sequelae. In all subjects except subject 2, COVID-19 was confirmed with PCR. Subjects 1, 2 and 4 had normal levels of IgM and IgG without measurable counts of CD19 cells prior to COVID-19. Subject 3 administered the last dose of ofatumumab 24 days prior to COVID-19 symptoms, but had a gap of 28 weeks of ofatumumab application beforehand due to low IgM levels. Subject 4 received COVID-19 vaccinations before second testing, so second testing and T-cell immunity testing were not performed. Subjects who were CD19 depleted did not had measurable levels of SARS-Cov2 IgG antibodies. Subject 3 had first and second SARS-COV2 titer of 118 U/ml and > 250 U/ml, respectively. All three pwMS showed T cell immunity against SARS-CoV-2. Quotient of basal spots divided by interferon-γ secreting spot forming units were 4, 8 and 14.7 SI in subjects 1, 2 and 3, respectively (>3 considered reactive). Conclusion While no antibody response was observed in pwMS who were CD19+ lymphocyte depleted, T cell immunity against SARS-CoV-2 was observed in all three pwMS treated with ofatumumab. Graphical abstract Unlabelled Image |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|